Capecitabine in Combination with Docetaxel in First Line in HER2-NegatÃve Metastatic Breast Cancer: an Observational Study (NDA@SZTAKI, Nemzeti Digitális Adattár, National Digital Data Archive)

in English |
magyarul

Betûméret: Súgó

NDA

Bejelentkezés

Regisztráció

Kapcsolat

MTA SZTAKI DSD
szotar.sztaki.hu

Capecitabine in Combination with Docetaxel in First Line in HER2-NegatÃve Metastatic Breast Cancer: an Observational Study

Metaadatok

Tartalom:	http://real.mtak.hu/43989/
Archívum:	MTA Könyvtár
Gyûjtemény:	Status = In Press Type = Article
Cím:	Capecitabine in Combination with Docetaxel in First Line in HER2-NegatÃve Metastatic Breast Cancer: an Observational Study
Létrehozó:	KÃ³szÃ³, RenÃ¡ta SÃ¡ntha, DÃ³ra BÃ¼di, LÃ¡szlÃ³ ErfÃ¡n, JÃ³zsef GyÅ‘rfy, KÃ¡roly HorvÃ¡th, Zsolt Kocsis, Judit Landherr, LÃ¡szlÃ³ Hitre, Erika MÃ¡hr, KÃ¡roly Pajkos, GÃ¡bor PÃ¡pai, Zsuzsanna KahÃ¡n, Zsuzsanna
Kiadó:	Springer Netherlands
Dátum:	2017
Téma:	RC0254 Neoplasms. Tumors. Oncology (including Cancer) / daganatok, tumorok, onkolÃ³gia
Tartalmi leírás:	Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 Â± 3.0 months. Time to treatment failure was 4.6 Â± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer. Keywords CapecitabineDocetaxelHER2-negative metastatic breast cancerToxicity
Nyelv:	angol
Típus:	Article PeerReviewed info:eu-repo/semantics/article
Formátum:	text
Azonosító:	http://real.mtak.hu/43989/1/Capecitabine_in_Combination_wit... KÃ³szÃ³, RenÃ¡ta and SÃ¡ntha, DÃ³ra and BÃ¼di, LÃ¡szlÃ³ and ErfÃ¡n, JÃ³zsef and GyÅ‘rfy, KÃ¡roly and HorvÃ¡th, Zsolt and Kocsis, Judit and Landherr, LÃ¡szlÃ³ and Hitre, Erika and MÃ¡hr, KÃ¡roly and Pajkos, GÃ¡bor and PÃ¡pai, Zsuzsanna and KahÃ¡n, Zsuzsanna (2017) Capecitabine in Combination with Docetaxel in First Line in HER2-NegatÃve Metastatic Breast Cancer: an Observational Study. PATHOLOGY AND ONCOLOGY RESEARCH. pp. 1-7. ISSN 1219-4956 (In Press)
Kapcsolat:	http://real.mtak.hu/43989/ http://dx.doi.org/10.1007/s12253-016-0129-7 MTMT:3151638; doi:10.1007/s12253-016-0129-7